Latest News

Latest News

Why Medical Electronics Are the Hardest E-Waste to Recycle

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

read more
Weekly News Roundup | 9 November 2026

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

read more
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

A Regulatory Playbook for SaMD and Digital Health

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

read more
Weekly News Roundup | 12 October 2026

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

read more
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....

read more
Viatris Pacira Acquisition: What the $1.65bn Deal Buys

Viatris Pacira Acquisition: What the $1.65bn Deal Buys

The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...

read more
GLP-1 Therapy: More Than Numbers on a Scale

GLP-1 Therapy: More Than Numbers on a Scale

The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...

read more
Clinical Trial Results | 9 October 2026

Clinical Trial Results | 9 October 2026

The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...

read more
Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...

read more
A Regulatory Playbook for SaMD and Digital Health

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

read more
Weekly News Roundup | 12 October 2026

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

read more
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....

read more
Viatris Pacira Acquisition: What the $1.65bn Deal Buys

Viatris Pacira Acquisition: What the $1.65bn Deal Buys

The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...

read more
GLP-1 Therapy: More Than Numbers on a Scale

GLP-1 Therapy: More Than Numbers on a Scale

The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...

read more
Clinical Trial Results | 9 October 2026

Clinical Trial Results | 9 October 2026

The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...

read more
Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...

read more
The Future of Diagnostics Is Molecularly Precise

The Future of Diagnostics Is Molecularly Precise

The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...

read more
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...

read more

Further News

GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows

The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?

Divarasib approval has no confirmed date, but Roche’s own guidance points to 2027. Roche’s Pharma Day slides of 28 September 2026 list US and EU approval as a 2027 milestone. No regulatory filing for the KRAS G12C inhibitor had been announced in the sources reviewed...

Beyond Screen Time: How Digital Habits Shape Attention and Memory

As digital platforms make information increasingly accessible, the challenge is no longer simply how much we consume, but how our digital habits affect the way we process, retain, and use it. Scrolling through social media can expose us to hundreds of pieces of...

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...

What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers

Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...

Imdelltra Imfinzi Approval: When Could First-Line Use Begin?

No filing for Imdelltra Imfinzi approval in first-line maintenance had been announced on 26 October 2026. DeLLphi-305 showed a hazard ratio for death of 0.42.

    OOS Investigation: A Solubility-Related HPLC Assay Failure

    A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

    Pharma’s Digital Maturity Divide Is Holding Back AI Adoption

    AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...

    UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks

    UK biotech venture capital hit £2.84bn in nine months of 2026. See the Q3 deals, the seed slump and what BIA wants from the Budget.

      Connecting ADME and Mouse Models in Preclinical Oncology

      In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.